Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Persistence of cardiovascular risk after rofecoxib discontinuation.

× No keyword cloud information.

5 in total

1. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245

2. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.

Authors: Leon J Thal; Steven H Ferris; Louis Kirby; Gilbert A Block; Christopher R Lines; Eric Yuen; Christopher Assaid; Michael L Nessly; Barbara A Norman; Christine C Baranak; Scott A Reines
Journal: Neuropsychopharmacology Date: 2005-06 Impact factor: 7.853

3. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

Authors: Joseph S Ross; David Madigan; Kevin P Hill; David S Egilman; Yongfei Wang; Harlan M Krumholz
Journal: Arch Intern Med Date: 2009-11-23

4. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.

Authors: John A Baron; Robert S Sandler; Robert S Bresalier; Angel Lanas; Dion G Morton; Robert Riddell; Erik R Iverson; David L Demets
Journal: Lancet Date: 2008-10-14 Impact factor: 79.321

5. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.

Authors: Bruce M Psaty; Richard A Kronmal
Journal: JAMA Date: 2008-04-16 Impact factor: 56.272

5 in total

4 in total

1. A model for dissemination and independent analysis of industry data.

Authors: Harlan M Krumholz; Joseph S Ross
Journal: JAMA Date: 2011-10-12 Impact factor: 56.272

Review 2. Molecular cancer prevention: Current status and future directions.

Authors: Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal: CA Cancer J Clin Date: 2015-08-18 Impact factor: 508.702

3. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study.

Authors: Anne-Marie Schjerning Olsen; Emil L Fosbøl; Jesper Lindhardsen; Charlotte Andersson; Fredrik Folke; Mia B Nielsen; Lars Køber; Peter R Hansen; Christian Torp-Pedersen; Gunnar H Gislason
Journal: PLoS One Date: 2013-01-30 Impact factor: 3.240

4. Who has used internal company documents for biomedical and public health research and where did they find them?

Authors: L Susan Wieland; Lainie Rutkow; S Swaroop Vedula; Christopher N Kaufmann; Lori M Rosman; Claire Twose; Nirosha Mahendraratnam; Kay Dickersin
Journal: PLoS One Date: 2014-05-06 Impact factor: 3.240

4 in total